Business Wire

MAIRE-TECNIMONT

Share
Maire Tecnimont Sues NatWest Bank in UK Court Over “Push Payment” Fraud

Maire Tecnimont Group, the Italian engineering multinational, is bringing legal action in the High Court in London against NatWest, following the bank’s failure to stop it falling victim to a “push-payment” fraud.

In 2018, Maire Tecnimont’s subsidiary in Saudi Arabia was duped (via an internal email account hacked by unidentified criminal elements) into sending $5 million to a bank account held with NatWest.

Despite this account having seen very little activity in the preceding period, and none involving such large sums, NatWest did not freeze the account pending further investigation. The controller of the NatWest account then appears to have almost immediately dispersed the stolen money in a flurry of numerous large payments to bank accounts in several different countries. NatWest allowed these payments to take place, despite the fact that they prompted two internal fraud alerts at the UK bank. Maire Tecnimont’s legal action claims this was a breach of the bank’s obligations under UK regulations against money laundering and terrorist financing. The funds paid out of the NatWest account became untraceable, for all practical purposes. They have not been recovered and are presumed to have fallen into criminal hands.

Maire Tecnimont is suing for $3.76 million - the amount still left in the account when NatWest’s first fraud alarm was triggered - plus interest and costs. According to the claim, Natwest fell short of standards of commercially acceptable conduct for a bank in relation to the prevention of fraud, money laundering, terrorist financing and financial crime.

The legal action argues that banks have a responsibility to take appropriate steps to prevent the dissipation of stolen or laundered funds. It may create clarity in what is currently an uncertain area of English law by establishing whether banks are required to prevent all fraud perpetrated using their accounts, not just fraud against the bank’s own customers.

Robert Wynn Jones of Mishcon de Reya, legal representative of Maire Tecnimont, said:

“Maire Tecnimont confirms it is suing NatWest over its lamentable failure to prevent a push-payment fraud through which the company lost millions of dollars.

“It is unacceptable and, frankly, inexplicable that NatWest did not prevent this fraud. The sudden appearance of such a large sum of money originating overseas into an essentially dormant bank account should have rung alarm bells. The bank has heavy anti-money laundering and anti-terrorism obligations, to say nothing of its general responsibility to protect banking customers. All of these controls failed.

“NatWest is a systemically-important UK bank with millions of customers. If it doesn’t have adequate safeguards to protect people against this kind of confidence scam, that is concerning for everybody.”

The legal action has been filed by Tecnimont Arabia Limited, a subsidiary of Maire Tecnimont SpA, which is represented by Robert Wynn Jones and John Sendama of Mishcon de Reya LLP. The claim number is LM-2020-000077.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release

79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha

Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release

Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly

Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release

Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit

Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release

New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye